|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Interferon Sciences |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002018 |
Purpose
To conduct a double-blind, randomized, dose ranging study of an orally administered low dose interferon alfa-n3 (IFN-An3) immunomodulator in the treatment of symptomatic HIV+ subjects.
| Condition | Intervention |
|---|---|
|
HIV Infections |
Drug: Interferon alfa-n3 |
| Study Type: | Interventional |
| Study Design: | Treatment, Double-Blind |
| Official Title: | Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 6 weeks of study entry:
Prior Treatment:
Excluded within 2 weeks of study entry:
Active intravenous (IV) drug abuse.
Contacts and Locations
More Information
| Study ID Numbers: | 069B, 90-355ME |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002018 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Interferon Type I |
|
Anti-Infective Agents Sexually Transmitted Diseases, Viral Interferon Type I, Recombinant Slow Virus Diseases Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Infection Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Retroviridae Infections Interferon-alpha RNA Virus Infections |
Immune System Diseases Growth Substances Acquired Immunodeficiency Syndrome Interferons Antiviral Agents Angiogenesis Inhibitors Immunologic Deficiency Syndromes Pharmacologic Actions Virus Diseases HIV Infections Sexually Transmitted Diseases Lentivirus Infections Interferon Alfa-2a |